Details

Autor(en) / Beteiligte

• Cheng, Wen-Hsing
• Combs, Gerald F.

Titel

Invited commentary in response to: selenium supplementation lowers insulin resistance and markers of cardio-metabolic risk in patients with congestive heart failure: a randomised, double-blind, placebo-controlled trial

Ist Teil von

• British journal of nutrition, 2018-07, Vol.120 (1), p.1-2

Ort / Verlag

Cambridge, UK: Cambridge University Press

Erscheinungsjahr

2018

Link zum Volltext

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Effects on type 2 diabetes risk among non-deficient subjects have been mixed; no effects were observed among adult subjects of the Selenium and Vitamin E Cancer Prevention Trial (SELECT)(4) and among younger adult subjects of the Selenium Trial with selenised yeast(5), but there was an increased risk among older adults in both the Selenium Trial(5) and the Nutritional Prevention of Cancer (NPC) trial(6). On the basis of changes in several metabolic and cardiovascular parameters (e.g. decreased insulin, LDL-cholesterol and C-reactive protein concentrations; increased HDL-cholesterol, total antioxidant capacity and glutathione concentrations), the authors concluded that Se supplementation benefited the treatment group, suggesting a protective role of Se supplementation in alleviation of the metabolic syndrome in patients with congestive heart failure. [...]at adequate and greater intakes, Se is increasingly incorporated non-specifically into all proteins by replacement of methionine with selenomethionine residues(16). [...]as we have pointed out, this question must be addressed in reference not only to health status but also to subject Se status, as both can affect the metabolic utilisation of this essential nutrient. [...]trials must be careful to characterise subject baseline Se status, as well as the specific identity of the intervention and control agents.